NCCN 2013 Congress Series: Utilizing Guidelines to Customize Patient Care in Non-Small Cell Lung Cancer™

Chicago, IL US
October 15, 2013

This congress is an educational program that addresses health care professionals' need to be educated on current and emerging evidenced-based scientific data for accurate and timely clinical evaluation of patients with non-small cell lung cancer. Participants will learn how to implement the NCCN Guidelines recommendations into their practice and gain a clear understanding of the most current treatment recommendations for non-small cell lung cancer.

Target Audience

This educational program is designed to meet the educational needs of medical oncologists, radiation oncologists, surgical oncologists, pathologists, nurses, pharmacists, and other healthcare professionals who manage patients with non-small cell lung cancer.

Learning Objectives

Following this congress, participants should be able to:

NEWER TREATMENT OPTIONS IN LOCAL DISEASE

  • Describe the appropriate use of video-assisted thoracic surgery (VATS) in the treatment of early stage non-small cell lung cancer.
  • Describe the appropriate use of stereotactic ablative radiotherapy (SABR) in the treatment of early stage non-small cell lung cancer.
  • Apply a multidisciplinary approach to making treatment recommendations for patients with early stage non-small cell lung cancer.

BIOMARKERS AND TESTING IN LUNG CANCER

  • Discuss the considerations and challenges of obtaining appropriate tissue samples.
  • Describe the molecular testing considerations for patients with ALK rearrangements and EGFR mutations.
  • Describe the role of the pathologist on the oncology healthcare team.

TREATMENT OF ADVANCED DISEASE

  • Describe how molecular testing can be used to select more appropriate treatment options and help improve outcomes for patients with advanced adenocarcinoma.
  • Discuss the optimal therapeautic management of patients with EGFR mutations and ALK gene rearrangements.
  • Discuss the role of maintenence therapy in non-small cell lung cancer.
Additional information
Supporters: 

Supported by educational grants from

  • Astellas Scientific and Medical Affairs, Inc.
  • Genentech
  • Lilly USA, LLC

Supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Supported by the Varian Medical Systems Foundation, a corporate advised fund of Silicon Valley Community Foundation

Course summary
Available credit: 
  • 2.25 Participation
  • 2.25 Nurse
  • 2.25 Pharmacist
  • 2.25 Physician
Course opens: 
10/14/2013
Course expires: 
12/31/2013
Event starts: 
10/15/2013 - 5:30pm EDT
Event ends: 
10/15/2013 - 8:00pm EDT
Cost:
$0.00
Add to calendar: 
Prentice Women's Hospital
250 East Superior Street
Harris Atrium and Conference Room L
Chicago, IL 60611
United States

Jyoti D. Patel, MD  (Moderator)
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Christine M. Lovly, MD, PhD
Vanderbilt-Ingram Cancer Center

Renato Martins, MD, MPH
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance

Stephen C. Yang, MD
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

 

View the complete agenda

This activity is approved for AMA PRA Category 1 Credit(s)™. Nursing and pharmacy (ACPE) credits are also provided. View complete accreditation details.

Available Credit

  • 2.25 Participation
  • 2.25 Nurse
  • 2.25 Pharmacist
  • 2.25 Physician

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Reader or other PDF reader software for certificate viewing/printing